Keyword: Edwards Lifesciences
The agreement sees Boston Scientific buy $90 million of Millipede stock and gain the right to acquire the rest of the business for up to $450 million.
The takeover gives Edwards control of a technology to repair the hearts of patients with the degenerative form of mitral valve disease.
Medtronic has posted a look at data on the first 50 patients treated with its transcatheter mitral valve replacement (TMVR) system.
Edwards Lifesciences has earned FDA clearance for its blood flow monitoring platform.
Following a U.K. court's mixed decision, a German court found Edwards infringed two Boston Scientific patents, while Boston Sci violated one Edwards patent.
After months of patent squabbling between Boston Scientific and Edwards, a U.K. court has deemed one of Boston Sci’s heart valve patents invalid.
Edwards Lifesciences has penned a deal to buy Valtech Cardio for up to $690 million, less than the heart valve company looked set to be acquired for last year.
Edwards Lifesciences has received a CE mark for its hypotension indicator, which alerts healthcare clinicians to the potential of abnormally low blood pressure in surgical and critical care patients before such an event occurs.
Edwards Lifesciences earned a CE mark for its resilient aortic valve, the first valve that incorporates a novel tissue technology aimed at cutting down calcification that affects other valve replacements.